- Terminal cancer patients who receive chemotherapy in the last months of their lives are less likely to die where they want and are more likely to undergo invasive medical procedures than those who do not receive chemotherapy.
Tags: chemotherapy, EndOfLife
- Nivolumab, a drug that unleashes the immune system to attack cancer, now shown to produce lasting remissions and hold the disease in check — for more than two years, in some cases — in many patients with advanced melanoma, according to a new study by Dana-Farber researchers and colleagues.
Tags: Melanoma, Immunotherapy
- A normal enzyme called SYK pairs with FLT3, the most commonly mutated enzyme found in acute myelogenous leukemia, to promote progression of the cancer and its resistance to treatment with FLT3-blocking drugs, which may explain relatively poor results in clinical studies. In a mouse model, treatment with a combination of drugs to inhibit the two enzymes was more effective than treatment with either drug alone.
Tags: chemotherapy, BasicResearch, ChildhoodCancer, Leukemia
- Tobacco use is the leading cause of preventable illness and death in the United States. Dana-Farber Cancer Institute applauds the decision by CVS Caremark to stop sales of all cigarettes and tobacco products by October.
Tags: Smoking, Prevention
- Dana-Farber researchers found that in patients with advanced melanoma using the immunotherapy ipilimumab, presence of higher levels of the protein vascular endothelial growth factor (VEGF) in the blood was associated with a poorer response, suggesting that combining immunotherapy with VEGF inhibitors may be a potential option for these patients.
Tags: Melanoma, SkinCancer, Immunotherapy
- Almost 90 percent of children treated for low-grade gliomas are alive 20 years later and few die from the tumor as adults. However, children whose treatment included radiation had significantly lower long-term survival rates.
Tags: ChildhoodCancer, Radiation, BrainTumors
- Ursula Matulonis, MD, the director of the Gynecological Cancer Treatment Center in the Susan F. Smith Center for Women’s Cancers at Dana-Farber receives a $900,000 grant from the Ovarian Cancer Research Foundation (OCRF) to test new combinations of targeted drugs against the disease.
Tags: Grants, OvarianCancer, GynecologicCancers
- An altered radiation treatment schedule for the most common and lethal form of brain cancer extended survival times a new study by researchers at Dana-Farber Cancer Institute and other organizations has shown.
Tags: Radiation, BrainTumors
- An analysis of clinical trial data led by Dana-Farber researches showed that patients with advanced kidney cancer lived an average of seven months longer if they were taking a common type of high blood pressure medication during treatment.
- Dana-Farber researchers have found that a combination of two already-in-use drugs may have an effect on stopping the growth of the most common genetic subtype of lung cancer setting the stage for clinical trials.
Tags: LungCancer, TargetedTherapy
Showing 1-10 of 476 items